<DOC>
	<DOC>NCT00758342</DOC>
	<brief_summary>To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.</brief_summary>
	<brief_title>Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Angle-Closure</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>≥ 18 years; CACG (Chronic Angle Closure Glaucoma) ≥ 1eye have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=1932 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes clinical stability of VA (Visual Acuity) and optic nerve throughout the study Abnormality restricts exam of the fundus or anderior chamber conjunctivitis, keratitis or uveitis unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days4weeks ocular surgery prior to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>IOP lowering efficacy and safety of Azopt plus Travatan</keyword>
</DOC>